Clinical Trials Browser

Phase 1/2 × Has results × Leukemia, Mast-Cell × Clear all

NCT03214666 2022-11-10

GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

Phase 1/2 Terminated

12 enrolled 20 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Mastocytosis, Systemic